Colon exam doesn’t finish the job

Share and Enjoy

New ‘hand’ may alleviate phantom pain

JENA, Germany (UPI) — Amputees suffering from “phantom pain” may get relief from a modified prosthetic that can convince the brain the body part still exists, researchers say.

Scientists at the University of Jena in Germany say phantom pain often lasts for years, and sometimes for a lifetime, often putting amputees at risk of mediation addiction from high dosages of painkillers, a university release said Friday.

Researchers say they’ve produced a modified prosthetic hand than can reduce phantom pain following amputation by using a stimulation unit in the hand’s cuff connected to the remaining part of the upper arm.

Modern prosthetic hands have pressure sensors meant to regulate the strength of grip of the artificial hand depending on what the wearer is trying to pick up, such as a raw egg or a hammer.

The stimulation unit in the modified hand takes feedback from the sensors and “talks” to the wearer’s brain, Dr. Gunther Hofmann of the Jena Department for Trauma, Hand and Reconstructive Surgery says.

“Our system is now able to transmit this sensory information from the hand to the upper arm,” Hofmann says.

Brain structures responsible for processing sensory information coming from the lost body part are “out of work” following an amputation and try to reorganize themselves, often leading to sensations of pain in a “phantom” hand, the Jena researchers say. By giving the appropriate brain structure sensory input from the “hand” it is meant to control, the reorganization can be prevented or reversed, thus eliminated phantom pain, they say.

Copyright 2010 by United Press International

Sourced & published by Henry Sapiecha

Share and Enjoy

Cell reprogramming breakthrough could mend broken hearts

Heart disease remains one the biggest killers in the Western world. When a heart attack or heart failure occurs, permanent damage often results, destroying live cells and leaving the patient with irreversible scarring. Now scientists at the Gladstone Institute of Cardiovascular Disease (GICD) have discovered a new technique to create healthy beating heart cells from structural cells, opening up the possibility of regenerating damaged hearts. Read More

Received & published by Henry Sapiecha

Share and Enjoy

3D imaging technique provides clearer roadmap to remove deadliest form of skin cancer

Even though melanoma is one of the less common types of skin cancer, it accounts for the majority of skin cancer deaths – around 75 percent. The five-year survival rate for early stage melanoma is very high (98 percent), but the rate drops precipitously if the cancer is detected late or there is recurrence. So a great deal rides on the accuracy of the initial surgery, where the goal is to remove as little tissue as possible while obtaining “clean margins” all around the tumor. So far no imaging technique has been up to the task of defining the melanoma’s boundaries accurately enough to guide surgery – until now. Read More

Received & published by Henry Sapiecha

Share and Enjoy

FDA: Stem cell trial can proceed

WASHINGTON (UPI) — The Food and Drug Administration has given approval to proceed with the world’s first human clinical trial of a human embryonic stem cell-based therapy.

Geron Corp., headquartered in Menlo Park, Calif., says it will proceed with its trial of GRNOPC1, a stem-cell therapy intended to treat patients with acute spinal cord injury, a company release said Friday.

“We are pleased with the FDA’s decision to allow our planned clinical trial of GRNOPC1 in spinal cord injury to proceed,” Geron President and Chief Executive Officer Thomas B. Okarma said. “Our goals for the application of GRNOPC1 in subacute spinal cord injury are unchanged — to achieve restoration of spinal cord function by the injection of … progenitor (stem) cells directly into the lesion site of the patient’s injured spinal cord.”

“The neurosurgical community is ready to begin the clinical testing of this new approach to treating devastating spinal cord injury,” said Richard Fessler, professor of neurological surgery at the Feinberg School of Medicine at Northwestern University. “If found to be safe and effective, the therapy would provide a viable treatment option for thousands of patients who suffer severe spinal cord injuries each year.”

Copyright 2010 by United Press International

Sourced & published by Henry Sapiechas

Share and Enjoy

Sexually Transmitted Diseases

The Cancer-Causing Sex Virus

Matthew Herper, 07.21.10, 04:15 PM EDT

HPV–known for causing cervical cancer–is

emerging as the leading cause of throat cancer in

men. Should they get the vaccine too?

Nine Things You Need To Know About HPV

Martin Duffy, a Boston consultant and economist, thought he just had a sore throat. When it persisted for months, he went to the doctor and learned there was a tumor on his tonsils.

Duffy, now 70, had none of the traditional risk factors for throat cancer. He doesn’t smoke, doesn’t drink and has run 40 Boston marathons. Instead, his cancer was caused by the human papilloma virus (HPV), which is sexually transmitted and a common cause of throat and mouth cancer.

HPV tumors have a better prognosis than those caused by too many years of booze and cigarettes. But Duffy “is in the unlucky 20%” whose cancer comes back–despite rounds of chemotherapy and radiation that melted 20 more pounds off a lean 150-pound frame. Now the cancer has spread throughout his throat, making eating and talking difficult. “I made my living as a public speaker,” he says. “Now I sound like Daffy Duck.” Duffy believes he has only a few months left. “How do you tell the people you love you love them?” he asks.

Nine Things You Need To Know About HPV

//

Most strains of the HPV virus are harmless, but persistent infections with two HPV strains cause 70% of the 12,000 cases of cervical cancers diagnosed annually in the U.S. Other forms of the sexually transmitted virus can cause penile and anal cancer, and genital warts. The HPV throat cancer connection has emerged in just the last few years and is so new that the government doesn’t track its incidence. Researchers believe it is transmitted via oral sex. But top researchers estimate that there are 11,300 HPV throat cancers each year in the U.S.–and the numbers are growing fast as people have been having more sexual partners since the 1960s. By 2015 there could be 20,000 cases. For more surprising discoveries about HPV, read here.

These big numbers have some top researchers arguing that drug makers should test whether HPV vaccines now used to prevent cervical cancer in women can also prevent throat infections in boys. Two vaccines, Gardasil from Merck ( MRK – news – people ) and Cervarix from GlaxoSmithKline ( GSK – news – people ), are approved for preventing cervical cancer. Gardasil is approved for use in boys only to prevent genital warts.

// Vaccinating boys could stop this meteoric increase in throat cancer. “Clearly, boys need to be vaccinated,” says Marshall Posner, the incoming medical director of head and neck cancer at Mt. Sinai Medical Center in New York. “I want my kids to be vaccinated. I don’t see a downside to these vaccines.”

There’s only one problem: The vaccine manufacturers aren’t terribly hot on the idea. GlaxoSmithKline says it has no plans to study throat cancer. It adds that it is “committed to providing a vaccine specifically designed to protect against cervical cancer in girls and young women.”

Merck, the maker of Gardasil, seemed more interested a couple of years ago. In 2008 it funded Maura Gillison, the Ohio State University researcher who established the HPV-throat-cancer link in 2000, to do a pilot study to show that test could reliably detect HPV infection in the throat. The pilot study was successful. By early 2009 Gillison says that a larger study of the vaccine in throat cancer looked close to being green lit.

But after Merck agreed to buy rival Schering-Plough ( SGP – news – people ) for $41 billion in March 2009, interest in a big study seemed to evaporate, Gillison says. In a statement, Merck says that “due to competing research and business priorities, we decided not to move ahead with an efficacy study at this time.”

The drug makers’ reticence probably stems from a fear that a throat-cancer vaccine would be hard to get approved. Papilloma viruses usually cause cancer slowly, causing pre-cancerous lesions that take many years to blossom into full-fledged malignant tumors. Papilloma viruses cause the horn-like growths in rabbits that probably gave rise to myths of “jackalopes” in the American West. In the cervix, early abnormal growths can be picked up with a diagnostic test, the Pap smear. Clinical trials of Gardasil and Cervarix took advantage of this, measuring the number of pre-cancerous growths prevented by the vaccines.

But there are no easy-to-detect pre-cancers in the throat. Adolescent boys would have to be followed for decades to to see if the vaccine prevented throat cancer, an unlikely scenario. Short of this, studies could only look at the prevention of HPV throat infections, not cancer or cancer precursors directly. Approving a vaccine for wide use based on this type of short-term data would require a leap of faith that the Food and Drug Administration might not be willing to take.

Top researchers say the federal government needs to step in and fund the long study if drug companies cannot be persuaded to do it themselves. “I’m sorry Merck decided not to do it,” says Posner. “But in the end, this is a federal responsibility. It’s a public health issue.”

For his part, Martin Duffy thinks that drug companies’ complacent attitude toward throat cancer would be different if more of their employees were in his situation. “It will change real fast,” he says, “if one of their executives comes down with this disease.”

Sourced & published by Henry Sapiecha

Share and Enjoy

Scientists Grow New Lungs

Using ‘Skeletons’ of Old Ones

Science (June 28, 2010) — For someone with a severe, incurable lung disorder such as cystic fibrosis or chronic obstructive pulmonary disease, a lung transplant may be the only chance for survival. Unfortunately, it’s often not a very good chance. Matching donor lungs are rare, and many would-be recipients die waiting for the transplants that could save their lives.

Such deaths could be prevented if it were possible to use stem cells to grow new lungs or lung tissue. Specialists in the emerging field of tissue engineering have been hard at work on this for years. But they’ve been frustrated by the problem of coaxing undifferentiated stem cells to develop into the specific cell types that populate different locations in the lung.

Now, researchers from the University of Texas Medical Branch at Galveston have demonstrated a potentially revolutionary solution to this problem. As they describe in an article published electronically ahead of print by the journal Tissue Engineering Part A, they seeded mouse embryonic stem cells into “acellular” rat lungs — organs whose original cells had been destroyed by repeated cycles of freezing and thawing and exposure to detergent.

The result: empty lung-shaped scaffolds of structural proteins on which the mouse stem cells thrived and differentiated into new cells appropriate to their specific locations.

“In terms of different cell types, the lung is probably the most complex of all organs — the cells near the entrance are very different from those deep in the lung,” said Dr. Joaquin Cortiella, one of the article’s lead authors. “Our natural matrix generated the same pattern, with tracheal cells only in the trachea, alveoli-like cells in the alveoli, pneumocytes only in the distal lung, and definite transition zones between the bronchi and the alveoli.”

Such “site-specific” cell development has never been seen before in a natural matrix, said professor Joan Nichols, another of the paper’s lead authors. The complexity gives the researchers hope that the concept could be scaled up to produce replacement tissues for humans — or used to create models to test therapies and diagnostic techniques for a variety of lung diseases.

“If we can make a good lung for people, we can also make a good model for injury,” Nichols said. “We can create a fibrotic lung, or an emphysematous lung, and evaluate what’s happening with those, what the cells are doing, how well stem cell or other therapy works. We can see what happens in pneumonia, or what happens when you’ve got a hemorrhagic fever, or tuberculosis, or hantavirus — all the agents that target the lung and cause damage in the lung.”

The researchers have already begun work on large-scale experiments, “decellularizing” pig lungs with an eye toward using them to produce larger samples of lung tissue that could lead to applications in humans. They’re also taking on the challenge of vascularization — stimulating the growth of blood vessels that will enable the engineered tissues to survive outside the special bioreactors that the researchers now use to keep them alive by bathing them in a life-sustaining cocktail of nutrients and oxygen.

“People ask us why we’re doing the lung, because it’s so hard,” Cortiella said. “But the potential is so great, and the technology is here. It’s going to take time, but I think we’re going to create a system that works.”

Other authors of the Tissue Engineering Part A paper are UTMB research associate Jean Niles, associate professor Gracie Vargas, medical student Sean Winston, graduate student Shannon Walls, summer research fellows Andrea Brettler and Jennifer Wang, Andrea Cantu of Stanford University and Dr. Anthony Pham of Brown Medical School

Sourced & published by Henry Sapiecha

Share and Enjoy